{"id":"NCT02855944","sponsor":"pharmaand GmbH","briefTitle":"ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients","officialTitle":"ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-03-01","primaryCompletion":"2020-12-03","completion":"2022-09-16","firstPosted":"2016-08-04","resultsPosted":"2022-02-11","lastUpdate":"2023-06-09"},"enrollment":349,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Ovarian Cancer","Epithelial Ovarian Cancer","Fallopian Tube Cancer","Peritoneal Cancer"],"interventions":[{"type":"DRUG","name":"Chemotherapy","otherNames":["Cisplatin","carboplatin","carboplatin/paclitaxel","carboplatin/gemcitabine","paclitaxel"]},{"type":"DRUG","name":"Rucaparib","otherNames":["CO-338","AG 14699","PF 01367338","Rubraca"]}],"arms":[{"label":"Rucaparib","type":"EXPERIMENTAL"},{"label":"Chemotherapy","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy.","primaryOutcome":{"measure":"Investigator Assessed Progression-Free Survival (invPFS) by RECIST Version 1.1 for Rucaparib Versus Chemotherapy (Efficacy Population)","timeFrame":"Assessments every 8 weeks from Cycle 1 Day 1 (C1D1) until disease progression, death, or initiation of subsequent treatment. After 18 months on study, assessments every 16 weeks. Total follow-up was up to approximately 3.5 years.","effectByArm":[{"arm":"Rucaparib","deltaMin":7.4,"sd":null},{"arm":"Chemotherapy","deltaMin":5.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0010"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":77,"countries":["United States","Brazil","Canada","Czechia","Hungary","Israel","Italy","Poland","Russia","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":["39914419","35298906"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":66,"n":232},"commonTop":["Anaemia","Nausea","Alanine aminotransferase increased","Vomiting","Aspartate aminotransferase increased"]}}